Related references
Note: Only part of the references are listed.Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19
Ignatios Ikonomidis et al.
FOOD AND CHEMICAL TOXICOLOGY (2020)
Interleukin 6 trans-signalling and risk of future cardiovascular events
Louise Ziegler et al.
CARDIOVASCULAR RESEARCH (2019)
The shedding protease ADAM17: Physiology and pathophysiology
Friederike Zunke et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation
Stefan Rose-John
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Characterization of death receptor 3-dependent aortic changes during inflammatory arthritis
Jessica O. Williams et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)
Imbalanced gp130 signalling in ApoE-deficient mice protects against atherosclerosis
Gareth W. Jones et al.
ATHEROSCLEROSIS (2015)
Blocking IL-6 trans-Signaling Prevents High-Fat Diet-Induced Adipose Tissue Macrophage Recruitment but Does Not Improve Insulin Resistance
Michael J. Kraakman et al.
CELL METABOLISM (2015)
Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis
E. E. A. Arts et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions
Norihiro Nishimoto et al.
Modern Rheumatology (2014)
Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis
Alfonso Corrales et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Endothelial Dysfunction in Rheumatoid Arthritis The Role of Monocyte Chemotactic Protein-1-Induced Protein
Ming He et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?
Anne M. Kerola et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice
Harald Schuett et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Contractile, but not endothelial, dysfunction in early inflammatory arthritis: a possible role for matrix metalloproteinase-9
S. L. Reynolds et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor
Iris Navarro-Millan et al.
CLINICAL THERAPEUTICS (2012)
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Stefan Rose-John
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Validated methods for assessment of subclinical atherosclerosis in rheumatology
Gyoergy Kerekes et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis Up-Regulation of the Vascular Arginase Pathway
Clement Prati et al.
ARTHRITIS AND RHEUMATISM (2011)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Simon A. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
gp130 at the nexus of inflammation, autoimmunity, and cancer
J. S. Silver et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Jean-Michel Dayer et al.
RHEUMATOLOGY (2010)
Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness
Anna Sodergren et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Animal models of rheumatoid arthritis
Darren L. Asquith et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis
Mari A. Nowell et al.
JOURNAL OF IMMUNOLOGY (2009)
Cardiovascular morbidity and mortality in rheumatoid arthritis
Sherine E. Gabriel
AMERICAN JOURNAL OF MEDICINE (2008)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling -: Implications in the pathogenesis of rheumatoid arthritis
Mari A. Nowell et al.
ARTHRITIS AND RHEUMATISM (2006)
Carotid stiffness and the risk of new vascular events in patients with manifest cardiovascular disease. The SMART study
JM Dijk et al.
EUROPEAN HEART JOURNAL (2005)
Cardiovascular Death in Rheumatoid Arthritis A Population-Based Study
Hilal Maradit-Kremers et al.
ARTHRITIS AND RHEUMATISM (2005)
Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis
B Schieffer et al.
CIRCULATION (2004)
Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-α-converting enzyme (ADAM 17)
KJ Garton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses
T Jostock et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Share Paper
